Tuesday, December 10, 2024

Treating Patients Beyond Borders – Antengene Successfully Hosted Its First R&D Day

Antengene Corporation Limited, a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer and other life-threatening diseases, hosted two Investor R&D meetings this week to discuss the Company’s vision and R&D philosophy, strategy, capabilities and its commercial readiness to launch Xpovio® (Selinexor) in its markets. During the meetings, members of Antengene’s senior leadership team presented a comprehensive overview of the Company’s robust discovery and early clinical development portfolio and deep clinical pipeline, as well as Xpovio.

The event was held virtually for an English speaking audience and in a live meeting in Shanghai, China with invited investors and guests.

Also Read: Pacur To Acquire CAROLEX To Expand Global Position And Customer Reach

“Antengene is pleased to highlight the excellent progress on our mission of building a research-driven cancer-focused global biopharmaceutical company since it began operations in 2017. This year marks the Company’s transition to becoming a fully-integrated company, with launch of its first commercial asset and the build-out of its core capabilities in drug discovery, clinical development, manufacturing and commercialization” said Jay Mei, M.D., Ph.D., Founder, Chairman and Chief Executive Officer of Antengene. “As of today, the Company has secured 19 IND approvals, with more approvals expected by the end of this year and Q1 2022. These achievements, coupled with the Company’s 2020 IPO and ~US$430 million cash balance as of June 30, 2021, are a testament to Antengene’s operational excellence, efficiency and robust execution.”

Dr. Mei continued, “Cancer does not wait and neither do we. Antengene is pressing forward to bring disruptive medicines to patients in a relatively short period of time. I am optimistic about Antengene’s bright future. Our bold focus on new areas of cancer biology and targets, especially in drug resistant tumors, expansive pipeline, broad internal R&D portfolio, array of value-added partnerships, strong key opinion leader relationships and highly-qualified management team will enable Antengene to deliver best-in-class, first-in-class medicines to transform cancer care. Furthermore, our plans to expand our R&D organization and build a new drug discovery and development facility for biologics in Hangzhou will provide the support we need to deliver results with excellence.”

Focused Commercial Program, Starting with ATG-010 (selinexor)

Carefully Selected Target Markets – Antengene discussed its target markets (mainland China, South Korea, Taiwan, Hong Kong, Singapore, and Australia), selected based on unmet medical needs, insurance and reimbursement coverage, and GDP growth. Earlier-than-expected XPOVIO approval® in South Korea transformed Antengene into a commercial entity. Antengene reported positive receptivity in selinexor in mainland China, where an approval is anticipated around year-end 2021 or early 2022. Expectations were also outlined for additional marketing authorizations in between now and 2022.

Subscribe Now

    Hot Topics